03.14.22
The European Food Safety Authority (EFSA) has published an opinion that Arla Food Ingredients’ Peptigen IF-3080 protein hydrolysate is safe and suitable for infant formulas and follow-on formula products in the EU. Per EU regulations passed on February 22, the nutritional safety and suitability of all protein hydrolysates used in these formulas would need to be evaluated.
Peptigen IF-3080 is one of only a few milk protein hydrolysate ingredients to receive a positive EFSA opinion, and those which are not approved are or will be removed from the market.
The European Commission is expected to include Peptigen IF-3080 in the Commission Delegated Regulation (EU) 2016/17 within the coming 12 months, according to the company. Thereby, Arla Foods Ingredients’ Peptigen IF-3080 will be approved for use in infant and follow-on formulas sold in the EU. Until then, Arla Foods Ingredients can supply the protein hydrolysate to its EU customers for infant and follow-on formulas, which can then be prepared for launch.
“We are delighted by this opinion, which supports our reputation for having the industry’s highest levels of quality, innovation, and food safety,” Anders Steen Jørgensen, head of SBU pediatric at Arla Foods Ingredients, said.
Peptigen IF-3080 is one of only a few milk protein hydrolysate ingredients to receive a positive EFSA opinion, and those which are not approved are or will be removed from the market.
The European Commission is expected to include Peptigen IF-3080 in the Commission Delegated Regulation (EU) 2016/17 within the coming 12 months, according to the company. Thereby, Arla Foods Ingredients’ Peptigen IF-3080 will be approved for use in infant and follow-on formulas sold in the EU. Until then, Arla Foods Ingredients can supply the protein hydrolysate to its EU customers for infant and follow-on formulas, which can then be prepared for launch.
“We are delighted by this opinion, which supports our reputation for having the industry’s highest levels of quality, innovation, and food safety,” Anders Steen Jørgensen, head of SBU pediatric at Arla Foods Ingredients, said.
